Base de dados : MEDLINE
Pesquisa : D26.255.640 [Categoria DeCS]
Referências encontradas : 10387 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1039 ir para página                         

  1 / 10387 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29441973
[Au] Autor:Gong F; Niu J; Pei X
[Ti] Título:Clinical effects of dressing on patients with I-II phase pressure sores.
[So] Source:Pharmazie;71(11):665-669, 2016 Nov 02.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Angelica dahurica is a well-known traditional Chinese Medicine (TCM), while little information is available about its effects on pressure sores. We aimed to investigate the clinical effect of Angelica dahurica on patients with I-II phase pressure sores, as well as the underlying mechanism. METHODS: Patients (n = 98) with phase I and phase II pressure sores were enrolled and randomly assigned to control and treated groups. In addition to holistic nursing, patients in the control group received compound clotrimazole cream, while patients in the treated group received continuous 4 weeks of external application of Angelica dahurica dressing. Therapeutic effect was recorded, along with the levels of interleukin-8 (IL-8), epidermal growth factor (EGF), transforming growth factor (TGF)-ß, and vascular endothelial growth factor (VEGF). Besides, HaCaT cells were cultured with different concentrations of Angelica dahurica, and then cell viability, clone formation numbers, cell cycle, and levels of cyclin D1 and cyclin-dependent kinase (CDK) 2 were determined. RESULTS: The total effective rate in the treated group was significantly higher than in the control group. Levels of IL-8, EGF, TGF-ß, and VEGF were statistically increased by Angelica dahurica. In addition, the cell viability and clone formation numbers were significantly upregulated by Angelica dahurica in a dose-dependent manner. Also, the percentage of cells in G0/G1 phase, and levels of cyclin D1 and CDK2 were significantly elevated. CONCLUSION: Our results suggest that Angelica dahurica may provide an effective clinical treatment for I-II phase pressure sores.
[Mh] Termos MeSH primário: Angelica/química
Lesão por Pressão/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Bandagens
Ciclo Celular/efeitos dos fármacos
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Citocinas/biossíntese
Relação Dose-Resposta a Droga
Feminino
Seres Humanos
Peptídeos e Proteínas de Sinalização Intercelular/biossíntese
Masculino
Meia-Idade
Pomadas
Fitoterapia
Lesão por Pressão/metabolismo
Lesão por Pressão/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Cytokines); 0 (Intercellular Signaling Peptides and Proteins); 0 (Ointments)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6704


  2 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29191265
[Au] Autor:Gobbato AAM; Gobbato CARS; Moreno RA; Antunes NJ; De Nucci G
[Ti] Título:Dapaconazole versus ketoconazole in the treatment of interdigital tinea pedis.
[So] Source:Int J Clin Pharmacol Ther;56(1):31-33, 2018 Jan.
[Is] ISSN:0946-1965
[Cp] País de publicação:Germany
[La] Idioma:eng
[Mh] Termos MeSH primário: Antifúngicos/uso terapêutico
Imidazóis/uso terapêutico
Cetoconazol/uso terapêutico
Tinha dos Pés/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Masculino
Meia-Idade
Pomadas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole); 0 (Antifungal Agents); 0 (Imidazoles); 0 (Ointments); R9400W927I (Ketoconazole)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE
[do] DOI:10.5414/CP203124


  3 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29337672
[Au] Autor:Szulc-Musiol B; Dolinska B; Kolodziejska J; Ryszka F
[Ad] Endereço:1Department of Applied Pharmacy School of Pharmacy and the Division of Laboratory Medicine Medical University of Silesia, Poland.
[Ti] Título:Influence of plasma on the physical properties of ointments with quercetin.
[So] Source:Acta Pharm;67(4):569-578, 2017 Dec 20.
[Is] ISSN:1846-9558
[Cp] País de publicação:Croatia
[La] Idioma:eng
[Ab] Resumo:Effects of two independent variables - the content of quercetin (0 or 1 or 1.5 or 5 %) and the content of plasma (0 or 2 or 4 or 6 %) - on the organoleptic properties and rheological parameters of model formulations prepared on an amphiphilic base were estimated. The consistency of all ointments was uniform, and the content of quercetin and plasma lay within the predefined range. Tested ointments are non-Newtonian systems. The content of quercetin and plasma was found to have a significant effect on the rheological properties of the ointments. An increase in the content of plasma in ointments was accompanied by a significant increase in their hardness, viscosity and shear stress and a reduction of their spreadability. The best rheological properties were shown by formulation F-3, containing 1.5 % of quercetin and 2 % of plasma.
[Mh] Termos MeSH primário: Pomadas/metabolismo
Plasma/metabolismo
Quercetina/metabolismo
[Mh] Termos MeSH secundário: Seres Humanos
Pomadas/química
Tamanho da Partícula
Quercetina/química
Reologia
Viscosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Ointments); 9IKM0I5T1E (Quercetin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180131
[Lr] Data última revisão:
180131
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180117
[St] Status:MEDLINE


  4 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461266
[Au] Autor:Bao Q; Shen J; Jog R; Zhang C; Newman B; Wang Y; Choi S; Burgess DJ
[Ad] Endereço:University of Connecticut, School of Pharmacy, Storrs, CT 06269, United States.
[Ti] Título:In vitro release testing method development for ophthalmic ointments.
[So] Source:Int J Pharm;526(1-2):145-156, 2017 Jun 30.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:It is essential as well as challenging to develop a reliable in vitro release testing method for determining whether differences in release profiles exist between qualitatively and quantitatively equivalent ophthalmic ointment formulations. There is a lack of regulatory guidance on in vitro release testing methods for ophthalmic formulations. Three different in vitro release testing methods 1) USP apparatus 4 with semisolid adapters; 2) USP apparatus 2 with enhancer cells; and 3) Franz diffusion cells were investigated. Qualitatively and quantitatively equivalent ointments were prepared via hot melting and simple mixing methods using four different sources of excipients (i.e. white petrolatum). The ointment formulations were characterized for content uniformity, particle size, and rheological parameters. All the formulations showed adequate content uniformity and similar particle size. The ointments prepared via the hot melting processes showed higher rheological parameters, as did the ointments prepared using 'white' petrolatum that exhibited a yellowish color. The three in vitro release testing methods were compared and evaluated for reproducibility, discriminatory capability, and correlation with the rheological parameters. Compared with the compendial methods, the non-compendial method (Franz diffusion cells) showed poorer reproducibility. All three methods possessed the ability to discriminate between the ophthalmic ointments with manufacturing differences. However, the USP apparatus 4 method displayed the largest margin of discrimination between the release profiles of the different ophthalmic ointments. In addition, the in vitro release rate obtained using the USP apparatus 4 method showed the strongest logarithmic linear correlation with the rheological parameters (Power law consistency index (K value) and crossover modulus) compared to the other two methods.
[Mh] Termos MeSH primário: Administração Oftálmica
Liberação Controlada de Fármacos
Excipientes/química
Pomadas/análise
[Mh] Termos MeSH secundário: Química Farmacêutica
Tamanho da Partícula
Reprodutibilidade dos Testes
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Excipients); 0 (Ointments)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29217021
[Au] Autor:Ross M; Deschênes J
[Ad] Endereço:Department of Ophthalmology, McGill University Health Center, McGill University, Montreal, Que.. Electronic address: michael.ross4@mail.mcgill.ca.
[Ti] Título:Practice patterns in the interdisciplinary management of corneal abrasions.
[So] Source:Can J Ophthalmol;52(6):548-551, 2017 Dec.
[Is] ISSN:1715-3360
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To characterize the treatment and follow-up patterns of corneal abrasions at an academic health centre. METHODS: This is a retrospective review of 90 cases of corneal abrasions over a 2-year period at a tertiary care academic hospital, of which 75 were seen by the ophthalmology department. All consultations primarily for corneal abrasion, as determined by the emergency department physician, were included in the study. Information on treatment regimen, corneal findings by emergency and ophthalmology physicians, time between follow-ups, and final outcomes was collected. RESULTS: Seventy-five patients were seen by ophthalmology a median of 1 day after the emergency room visit. Twenty-five of these patients did not arrive for their subsequent follow-up appointment. Twenty-two of the abrasions were healed by the time of the ophthalmology examination, 51 patients had unhealed corneal abrasions, and 2 had corneal ulcers. Management was changed in 29 of the patients by ophthalmology. The most common management changes were hypertonic saline ointment for prophylaxis or treatment of recurrent erosion syndrome, followed by bandage contact lenses for comfort. CONCLUSIONS: Corneal abrasions are a common condition, and practice patterns for follow-up vary widely. Although the vast majority of patients do very well and likely would heal on their own without ophthalmology referral, it seems reasonable that patients with corneal abrasions are assessed once by an ophthalmologist immediately or possibly up to 1-2 days after the initial emergency visit, depending on the individual patient circumstances.
[Mh] Termos MeSH primário: Lesões da Córnea/terapia
Epitélio Anterior/lesões
Oftalmologistas/estatística & dados numéricos
Equipe de Assistência ao Paciente
Padrões de Prática Médica/estatística & dados numéricos
[Mh] Termos MeSH secundário: Centros Médicos Acadêmicos
Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Bandagens
Lentes de Contato
Serviço Hospitalar de Emergência
Feminino
Seres Humanos
Masculino
Meia-Idade
Pomadas
Equipe de Assistência ao Paciente/estatística & dados numéricos
Estudos Retrospectivos
Solução Salina Hipertônica/administração & dosagem
Centros de Atenção Terciária
Cicatrização
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Ointments); 0 (Saline Solution, Hypertonic)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171209
[St] Status:MEDLINE


  6 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29173498
[Au] Autor:Croaker A; King GJ; Pyne JH; Anoopkumar-Dukie S; Simanek V; Liu L
[Ad] Endereço:Southern Cross Plant Science, Southern Cross University, Lismore, NSW, Australia; Wesley Medical Research Institute, Wesley Hospital, Auchenflower, QLD, Australia; Quality Use of Medicines Network, Queensland, Australia.
[Ti] Título:Carcinogenic potential of sanguinarine, a phytochemical used in 'therapeutic' black salve and mouthwash.
[So] Source:Mutat Res;774:46-56, 2017 Oct.
[Is] ISSN:1873-135X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Black salves are escharotic skin cancer therapies in clinical use since the mid 19th century. Sanguinaria canadensis, a major ingredient of black salve formulations, contains a number of bioactive phytochemicals including the alkaloid sanguinarine. Despite its prolonged history of clinical use, conflicting experimental results have prevented the carcinogenic potential of sanguinarine from being definitively determined. Sanguinarine has a molecular structure similar to known polyaromatic hydrocarbon carcinogens and is a DNA intercalator. Sanguinarine also generates oxidative and endoplasmic reticulum stress resulting in the unfolded protein response and the formation of 8-hydroxyguanine genetic lesions. Sanguinarine has been the subject of contradictory in vitro and in vivo genotoxicity and murine carcinogenesis test results that have delayed its carcinogenic classification. Despite this, epidemiological studies have linked mouthwash that contains sanguinarine with the development of oral leukoplakia. Sanguinarine is also proposed as an aetiological agent in gallbladder carcinoma. This literature review investigates the carcinogenic potential of sanguinarine. Reasons for contradictory genotoxicity and carcinogenesis results are explored, knowledge gaps identified and a strategy for determining the carcinogenic potential of sanguinarine especialy relating to black salve are discussed. As patients continue to apply black salve, especially to skin regions suffering from field cancerization and skin malignancies, an understanding of the genotoxic and carcinogenic potential of sanguinarine is of urgent clinical relevance.
[Mh] Termos MeSH primário: Antissépticos Bucais/farmacologia
Pomadas/farmacologia
Fitoterapia
Extratos Vegetais/farmacologia
Sanguinaria/química
Dermatopatias/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Mouthwashes); 0 (Ointments); 0 (Plant Extracts)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171205
[Lr] Data última revisão:
171205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  7 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28471562
[Au] Autor:Ulanovsky I; Shnaider M; Geffen Y; Smolkin T; Mashiah T; Makhoul IR
[Ad] Endereço:Department of Neonatology, Rappaport Children's Hospital, Rambam Health Care Campus, affiliated with Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
[Ti] Título:Erythromycin Prophylaxis for Neonatal Conjunctivitis: Ointment Versus Drops.
[So] Source:Isr Med Assoc J;18(7):404-406, 2016 Jul.
[Is] ISSN:1565-1088
[Cp] País de publicação:Israel
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Due to a shortage of individualized erythromycin ointment (IEO), we switched to shared erythromycin drops (SED). Following this change, nurses claimed observing more cases of eye discharge. OBJECTIVES: To test whether switching from IEO to SED affected the rate of neonatal conjunctivitis (NC). METHODS: The study group included 14,916 neonates > 35 weeks of gestation, further divided into two birth periods of 12 months each: 1 January 2013 to 31 December 2013 (IEO) and 1 February 2014 to 31 January 2015 (SED). We compared the two birth periods with regard to three variables: clinical NC (number of conjunctival swabs/1000 neonates), bacterial NC (number of culture-positive swabs/1000 neonates), and bacterial growth percentage (number of culture-positive swabs/100 samples). RESULTS: Compared to 2012-2013, the period 2014-2015 included fewer cesarean deliveries and shorter length of stay (LOS). Clinical NC, bacterial NC and bacterial-growth percentage were not different between the two periods. Variables that were independently significantly associated with increased clinical NC included male gender (OR 1.48, CI 1.21-1.81) and LOS (OR 1.24, CI 1.18-1.29). LOS was associated with bacterial NC (OR 1.19, CI 1.11-1.28). Coagulase-negative staphylococci, Escherichia coli and Pseudomonas aeruginosa were the prevalent pathogens, though without difference between periods. CONCLUSIONS: Rates of clinical NC, bacterial NC and bacterial-growth percentage were not different between the study periods. Switching from IEO to SED had no effect on the NC rate.
[Mh] Termos MeSH primário: Antibacterianos/administração & dosagem
Cesárea/estatística & dados numéricos
Eritromicina/administração & dosagem
Oftalmia Neonatal/prevenção & controle
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Recém-Nascido
Tempo de Internação
Masculino
Pomadas
Oftalmia Neonatal/epidemiologia
Oftalmia Neonatal/microbiologia
Soluções Oftálmicas
Gravidez
Estudos Retrospectivos
Fatores de Risco
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Ointments); 0 (Ophthalmic Solutions); 63937KV33D (Erythromycin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  8 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28823881
[Au] Autor:Eichenfield LF; Call RS; Forsha DW; Fowler J; Hebert AA; Spellman M; Stein Gold LF; Van Syoc M; Zane LT; Tschen E
[Ad] Endereço:Division of Pediatric Dermatology, Rady Children's Hospital, San Diego, California; Departments of Dermatology and Pediatrics, University of California, San Diego, California. Electronic address: leichenfield@rchsd.org.
[Ti] Título:Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis.
[So] Source:J Am Acad Dermatol;77(4):641-649.e5, 2017 Oct.
[Is] ISSN:1097-6787
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Long-term topical treatment is often required for atopic dermatitis (AD), a chronic inflammatory skin disease. OBJECTIVE: To assess the long-term safety results from a multicenter, open-label, 48-week safety study (AD-303) of patients (N = 517) ≥2 years of age with mild to moderate AD who continued crisaborole treatment, a topical phosphodiesterase-4 inhibitor, after completing a 28-day phase 3 pivotal study (AD-301, AD-302). METHODS: Global disease severity was assessed in patients every 4 weeks, and if assessed as mild or greater, a 28-day treatment period with crisaborole applied twice daily was initiated. Adverse events (AEs), including treatment-emergent AEs (TEAEs), and serious AEs were analyzed. RESULTS: During the pivotal studies and AD-303, 65% of patients reported ≥1 TEAE, most of which were mild (51.2%) or moderate (44.6%) and considered unrelated to treatment (93.1%). The frequency and severity of TEAEs were consistent. The most frequently reported treatment-related AEs (overall, 10.2%) were dermatitis atopic (3.1%), application-site pain (2.3%), and application-site infection (1.2%). Nine patients (1.7%) discontinued the long-term study because of TEAEs. LIMITATIONS: Long-term efficacy was not analyzed. CONCLUSION: Crisaborole ointment had a low frequency of treatment-related AEs over 48 weeks of treatment of patients with AD.
[Mh] Termos MeSH primário: Compostos de Boro/efeitos adversos
Compostos Bicíclicos Heterocíclicos com Pontes/efeitos adversos
Dermatite Atópica/tratamento farmacológico
Fármacos Dermatológicos/efeitos adversos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Criança
Pré-Escolar
Dermatite Atópica/induzido quimicamente
Progressão da Doença
Feminino
Seres Humanos
Infecção/induzido quimicamente
Masculino
Meia-Idade
Pomadas
Dor/induzido quimicamente
Inibidores da Fosfodiesterase 4/efeitos adversos
Índice de Gravidade de Doença
Exacerbação dos Sintomas
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (AN2728); 0 (Boron Compounds); 0 (Bridged Bicyclo Compounds, Heterocyclic); 0 (Dermatologic Agents); 0 (Ointments); 0 (Phosphodiesterase 4 Inhibitors)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170822
[St] Status:MEDLINE


  9 / 10387 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28709667
[Au] Autor:Chan JL; Diaconescu AC; Horvath KA
[Ad] Endereço:Cardiothoracic Surgery Research Program, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland.
[Ti] Título:Routine Use of Topical Bacitracin to Prevent Sternal Wound Infections After Cardiac Surgery.
[So] Source:Ann Thorac Surg;104(5):1496-1500, 2017 Nov.
[Is] ISSN:1552-6259
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The development of sternal wound infections remains a serious complication after cardiac surgery. A number of studies have assessed the use of topical antibiotics placed on the sternal edges. We evaluated the routine use of bacitracin ointment applied over the sternotomy skin incision as a prophylactic measure against sternal wound infections. METHODS: A retrospective review of all coronary artery bypass graft and valve surgery cases performed at a single institution between 2006 and 2015 was performed (n = 1,495). Appropriate preoperative intravenous antibiotics were administered for all patients. Bacitracin topical antibiotic ointment was routinely applied to the sternal surgical incision after skin closure for all patients during this period. The incidence of sternal wound infection was assessed. RESULTS: During this 9-year experience, no episodes of deep sternal wound infections were observed, compared with a predicted rate of 0.29% (interquartile range: 0.19% to 0.46%) based on The Society of Thoracic Surgeons National Database risk calculator. Four episodes of superficial sternal wound infections were noted; gram-positive organisms were cultured in the majority of these cases. Bacitracin ointment was well tolerated by patients, with no serious adverse effects reported. CONCLUSIONS: This study suggests that the routine application of topical bacitracin over the surgical skin incision is safe after cardiac surgery. Deep sternal wound infections were notably absent during this period. As a readily available and inexpensive therapy, this simple intervention may be a useful adjunct strategy in preventing sternal wound infections.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Bacitracina/uso terapêutico
Ponte de Artéria Coronária/efeitos adversos
Implante de Prótese de Valva Cardíaca/efeitos adversos
Esternotomia/efeitos adversos
Infecção da Ferida Cirúrgica/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração Tópica
Idoso
Estudos de Coortes
Ponte de Artéria Coronária/métodos
Feminino
Seguimentos
Implante de Prótese de Valva Cardíaca/métodos
Seres Humanos
Masculino
Meia-Idade
Pomadas/uso terapêutico
Estudos Retrospectivos
Medição de Risco
Esternotomia/métodos
Infecção da Ferida Cirúrgica/prevenção & controle
Resultado do Tratamento
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Ointments); 1405-87-4 (Bacitracin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170716
[St] Status:MEDLINE


  10 / 10387 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28686044
[Au] Autor:Bakkiyaraj D; Sritharadol R; Padmavathi AR; Nakpheng T; Srichana T
[Ad] Endereço:a Nanotec-PSU Excellence Center on Drug Delivery System, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Thailand.
[Ti] Título:Anti-biofilm properties of a mupirocin spray formulation against Escherichia coli wound infections.
[So] Source:Biofouling;33(7):591-600, 2017 Aug.
[Is] ISSN:1029-2454
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Mupirocin ointment is a widely used topical drug for the treatment of bacterial skin infections. However, ointments have some limitations which motivated the development of a film forming spray of mupirocin. Mupirocin spray (2%) was formulated with Eudragit E100 as a film forming agent and tested for its antibacterial and anti-biofilm activities against Escherichia coli, a skin pathogen causing wound and surgical site infections. Treatment with mupirocin spray resulted in significant antibacterial and anti-biofilm activities (inhibition and disruption) with single spray and sub-actual dose concentrations at par with the commercial ointment concentration. The spray formulation was found to be non-toxic to fibroblast cells and greatly resisted removal from the site of application upon washing, in contrast to the ointment which was significantly removed after a single wash. This is the first study to develop and evaluate a spray formulation for mupirocin that forms a stable thin film for sustained release of the drug.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Biofilmes/efeitos dos fármacos
Escherichia coli/efeitos dos fármacos
Mupirocina/farmacologia
Dermatopatias Bacterianas/tratamento farmacológico
Infecções Estafilocócicas/tratamento farmacológico
Infecção dos Ferimentos/tratamento farmacológico
[Mh] Termos MeSH secundário: Acrilatos/química
Administração Cutânea
Aerossóis
Antibacterianos/administração & dosagem
Antibacterianos/toxicidade
Linhagem Celular
Sobrevivência Celular/efeitos dos fármacos
Composição de Medicamentos
Escherichia coli/isolamento & purificação
Seres Humanos
Mupirocina/administração & dosagem
Mupirocina/toxicidade
Pomadas
Polímeros/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Acrylates); 0 (Aerosols); 0 (Anti-Bacterial Agents); 0 (Eudragit E100); 0 (Ointments); 0 (Polymers); D0GX863OA5 (Mupirocin)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171102
[Lr] Data última revisão:
171102
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170708
[St] Status:MEDLINE
[do] DOI:10.1080/08927014.2017.1337100



página 1 de 1039 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde